Author

C. J. Kearney

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Organism:mouse· 2 Approach:statistical model· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

R. W. Johnstone· 3 shared S. J. Vervoort· 3 shared J. Oliaro· 2 shared S. J. Hogg· 2 shared A. Paehler· 1 shared A. Ruefli-Brasse· 1 shared A. Wei· 1 shared B. T. Kile· 1 shared

Activity by Year

2019-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

R. W. Johnstone

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

BET Inhibition Enhances TNF Mediated Anti-Tumor Immunity

L. C. Wellinger, S. J. Hogg, D. M. Newman, T. Friess, D. Geiss, J. Michie, K. M. Ramsbottom, M. Bacac, T. Fauti, D. Marbach, L. Jarassier, P. Thienger, A. Paehler, L. A. Cluse, C. J. Kearney, , R. W. Johnstone

This paper identifies BET bromodomain inhibitors as agents that enhance anti-tumor immunity by sensitizing tumors to TNF-mediated cytotoxicity through suppression of NF-κB signaling.

bioRxiv · Feb 15, 2021Cancer Biology

Epigenetic reprogramming of plasmacytoid dendritic cells drives type I interferon-dependent differentiation of acute myeloid leukemias for therapeutic benefit

J. Salmon, I. Todorovski, S. J. Vervoort, K. L. Stanley, C. J. Kearney, L. Martelotto, F. Rossello, T. Semple, G. Mir Arnau, M. Zethoven, M. Bots, E. Vidacs, K. McArthur, E. Gressier, N. De Weerd, , R. W. Johnstone

The paper shows that inhibiting HDACs in AML promotes type I IFN production by pDCs, enhancing anti-tumor immunity and therapeutic benefit.

bioRxiv · Aug 23, 2020 · PreprintCancer Biology

Efficient CRISPR/Cas9 gene ablation in uncultured naive mouse T cells for in vivo studies

S. Nüssing, I. G. House, C. J. Kearney, S. J. Vervoort, P. A. Beavis, J. Oliaro, R. W. Johnstone, J. A. Trapani, I. A. Parish

This paper demonstrates efficient CRISPR/Cas9 gene ablation in uncultured naive mouse T cells for in vivo studies, showing gene deletion occurs independently of T cell activation.

bioRxiv · Aug 9, 2019Immunology